We report that a novel sulfonylamino compound, 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide (PEPA), selectively potentiates glutamate receptors of the AMPA subtype. PEPA (1-200 M) dose dependently potentiated glutamateevoked currents in Xenopus oocytes expressing AMPA (GluRAGluRD), but not kainate (GluR6 and GluR6ϩKA2) or NMDA (1 ϩ ⑀1-⑀4), receptor subunits. PEPA was effective at micromolar concentrations and, in contrast to the action of cyclothiazide, preferentially modulated AMPA receptor flop isoforms. At 200 M, PEPA potentiated glutamate responses by 50-fold in oocytes expressing GluRC flop (EC 50 ϳ50 M) versus only threefold for GluRC flip ; a similar preference for flop isoforms was observed for other AMPA receptor subunits. Dose-response analysis for GluRC flop revealed that 100 M PEPA produced a sevenfold increase in AMPA receptor affinity for glutamate. PEPA produced considerably weaker potentiation of kainate-evoked than glutamate-evoked currents, suggesting modulation of the process of receptor desensitization. In human embryonic kidney 293 cells transfected with AMPA receptor subunits, PEPA either abolished or markedly slowed the rate of onset of desensitization and potentiated steady-state equilibrium currents evoked by glutamate with subunit (GluRC Ն GluRD Ͼ GluRA) and splice-variant (flop Ͼ flip) selectivity similar to that observed in oocytes. Our results show that PEPA is a novel, flop-preferring allosteric modulator of AMPA receptor desensitization at least 100 times more potent than aniracetam.
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Allosteric modulation of the three subtypes of ionotropic glutamate receptors-AM PA, kainate, and NMDA receptors-is produced by a diverse spectrum of agents, including lectins, a variety of drugs, polyamines, and divalent cations. The unusually strong modulation of AM PA receptors by the benzothiadiazine and pyrrolidinone compounds cyclothiazide, aniracetam, and their derivatives (Ito et al., 1990; Isaacson and Nicoll, 1991; Tang et al., 1991; Vyklicky et al., 1991; Hestrin, 1992; Yamada and Rothman, 1992; Bertolino et al., 1993; Patneau et al., 1993; Yamada and Tang, 1993; Arai et al., 1994; Staubli et al., 1994a,b) is especially interesting, because these drugs potentiate excitatory synaptic transmission and have the potential for therapeutic use as nootropic agents.
AM PA receptors are hetero-oligomeric complexes, most likely pentamers (Wenthold et al., 1992; Ferrer-Montiel and Montal, 1996) , generated by the assembly of various combinations of four subunits named GluR A, GluRB, GluRC, and GluRD or GluR1, GluR2, GluR3, and GluR4, respectively (Hollmann et al., 1989; Boulter et al., 1990; Keinänen et al., 1990) . Each subunit exists in flip and flop isoforms generated by alternative splicing , and their expression is regulated both regionally and developmentally (Boulter et al., 1990; Keinänen et al., 1990; Sommer et al., 1990; Monyer et al., 1991) . Because the assembly of AMPA receptors containing more than one type of subunit appears not to require a fixed stoichiometry, it is possible to generate a diverse array of receptor subtypes that differ in important functional properties. For example, subunit composition can affect the affinity for various agonists and antagonists (Stein et al., 1992) . Splice-variant composition affects the kinetics of receptor deactivation, the rate of onset and recovery from desensitization, and modulation by cyclothiazide and aniracetam (Lomeli et al., 1994; Mosbacher et al., 1994; Partin et al., 1994) . Assembly of GluRB with other subunits reduces Ca 2ϩ permeability (Hollmann et al., 1991; Hume et al., 1991; Sommer et al., 1991) , single-channel conductance (Swanson et al., 1997) , and rectification resulting from channel block by polyamines (Verdoorn et al., 1991; Bowie and Mayer, 1995) .
Although the physiological significance of the cell-specific expression of AMPA receptor subunits and splice variants is not yet fully understood, it is likely that the regulation of receptor composition determines the kinetics and strength of transmission at glutamatergic synapses. As such, drugs that modulate AMPA receptors are both useful pharmacological tools as well as potential therapeutic agents. The modulation of AMPA receptors by aniracetam and cyclothiazide, the most thoroughly examined agents, reveals profound differences in potency, pharmacological selectivity, and mechanism of action. Aniracetam is effective at millimolar concentrations and preferentially modulates flop splice variants (Johansen et al., 1995; Partin et al., 1996) , whereas cyclothiazide is effective at micromolar concentrations and preferentially modulates flip splice variants (Partin et al., 1994 (Partin et al., , 1996 .
Here we report that a novel sulfonylamino compound, PEPA, which is structurally distinct from the previously characterized pyrrolidinone or benzothiadiazine compounds typified by aniracetam and cyclothiazide (see Fig. 1 ), potentiates currents of recombinant AM PA receptors expressed in Xenopus oocytes. PEPA is effective at micromolar concentrations, is selective for the AM PA subtype of glutamate receptors, and preferentially modulates flop splice variants. Rapid perf usion experiments in transfected human embryonic kidney 293 (H EK 293) cells show that potentiation by PEPA results primarily from attenuation of desensitization.
MATERIALS AND METHODS
Xenopus ooc yte e xpression system. Glutamate receptor expression in Xenopus oocytes was performed as described previously (Sekiguchi et al., 1994) . Briefly, cRNA was prepared from linearized cDNA encoding glutamate receptors by in vitro transcription. The cDNAs encoding rat GluR1 flop , GluR2 flop , GluR3 flop , GluR6, and K A2 were kindly provided by Dr. Steven Heinemann (The Salk Institute for Biological Studies, San Diego, CA). In Results, these are referred to as GluR A, GluRB, and GluRC to maintain consistent nomenclature with experiments on H EK 293 cells, which were performed with cDNAs from Dr. Peter Seeburg. The flip variants of GluR1, GluR2, and GluR3 were prepared from corresponding flop cDNAs by using site-directed mutagenesis (MutaGene Phagemid kit, Bio-Rad, Hercules, CA) as described previously (Sekiguchi et al., 1994; Matsui et al., 1995) . The mutations were confirmed by sequence analysis. Oocyte expression plasmids encoding GluRD flop and GluRD flip were provided by Dr. Seeburg (University of Heidelberg, Heidelberg, Germany). The R /G sites in GluR2 flip and GluR3 flip (both G versions) are the same as in their original flop clones; the sites in GluRD were R (flip) and G (flop). The cDNAs encoding mouse NMDA receptors were kindly provided by Dr. M. Mishina (University of Tokyo, Tokyo, Japan).
The concentration of the cRNA solution injected into oocytes was 1 mg /ml, and 50 nl of the solution was injected into an oocyte. The ratio of GluR A, GluRC, or GluRD to GluRB was 1:1, unless specified otherwise. Electrophysiological responses were recorded 4 -6 d after injection with a two-electrode voltage clamp at a holding potential of Ϫ100 mV, unless otherwise specified. Oocytes were perf used with frog Ringer's solution consisting of (in mM): 115 NaC l, 2 KC l, 1.8 C aC l 2 , and 10 H EPES, pH 7.2 with NaOH. PEPA was dissolved in dimethylsulfoxide (DMSO), usually at 100 mM, and added to frog Ringer's solution to yield final concentrations of 0.2-200 M; the final concentration of DMSO was no more than 0.2%. The pH of the frog Ringer's solution was not changed by adding 200 M PEPA. At room temperature no precipitation was observed in the PEPA-DMSO -frog Ringer's solution up to 200 M PEPA. Concanavalin A (Sigma, St. L ouis, MO) was dissolved in frog Ringer's solution (1 mg /ml), and the oocytes were incubated in this solution for ϳ3 min at room temperature before recording.
Rapid perf usion e xperiments in HEK 293 cells. Plasmids encoding cDNA clones of rat GluR A, GluRB, GluRC, and GluRD flip ( i ) and flop ( o ) in C M V expression vectors (gifts from Dr. Peter Seeburg) were prepared by alkaline lysis, followed by 2ϫ cesium chloride gradient purification. H EK 293 cells (ATCC CRL 1573) were plated at low density on 35 mm Petri dishes and transfected 24 hr later, using the calcium phosphate precipitation technique of Chen and Okayama (1987) . C ells were maintained in M EM with Earle's salts, 2 mM glutamine, and 10% fetal bovine serum. Heteromeric receptors were examined by cotransfection of GluR A, GluRC, or GluRD with GluRB (at a ratio of 1:2); heteromerization was confirmed by analysis of current-voltage plots as described previously (Partin et al., 1994) , and data were excluded for cells with significant inward rectification. Whole-cell recordings from isolated H EK 293 cells were obtained 40 -72 hr after transfection, using an Axopatch-200B amplifier (Axon Instruments, Foster C ity, CA), at a holding potential of Ϫ60 mV. E xtracellular recording solution contained (in mM): 145 NaC l, 5.4 KC l, 1.8 C aC l 2 , 1 MgC l 2 , 5 H EPES, and 0.01 mg /ml phenol red, pH 7.3, osmolarity 295 mOsm. Borosilicate glass pipettes (W PI 1B150F, World Precision Instruments, Sarasota, FL) had resistances of 2-5 M⍀ when filled with (in mM): 135 C sC l, 10 C sF, 0.5 CaCl 2 , 1 MgC l 2 , 10 H EPES, and 5 C s 4 -BAP TA, pH 7.2, osmolarity 295 mOsm. Solutions were applied at a flow rate of 0.67 ml /min controlled by a syringe pump (W PI sp220i) with a stepper motor-based fast perf usion system as described previously (Vyklicky et al., 1991) . Responses were filtered at 2-5 kHz (8-pole Bessel filter), digitized as required, and stored on a MacIntosh PPC 7600/132 computer by using a 16-bit AD converter (Instrutech I TC -16, Great Neck, N Y) under control of the data acquisition and analysis program Synapse (Synergy Research, Silver Spring, MD). The control barrel of the fast perf usion system contained normal extracellular solution; the other barrels contained 3 mM L-glutamate, 100 M PEPA, or both. PEPA was dissolved in DMSO at 100 mM before dilution in extracellular solution, and an equivalent final concentration of DMSO (0.1%) was added to all glutamate and control solutions not containing PEPA. The time constant of onset of desensitization ( des ) in the presence and absence of PEPA was fit by a single exponential f unction for all subunits except GluR A i , for which responses in the presence of PEPA were better fit by the sum of two exponentials (see Fig.  9A ). The onset ( on ) and recovery ( off ) from potentiation in response to rapid application of PEPA (see Fig. 8 
RESULTS
The action of PEPA (Fig. 1 ) on glutamate receptors was discovered via electrophysiological screening of compounds containing sulfonylamino groups, using the Xenopus oocyte expression system and poly(A ϩ ) mRNA prepared from rat brain. PEPA was synthesized originally in the process of developing thromboxane A2 receptor antagonists (Sato et al., 1994 (Sato et al., , 1995 , but the activity of PEPA on A2 receptors has not yet been tested. PEPA produced small inward current responses in oocytes expressing AMPA receptor flop splice variants but did not evoke current responses in control oocytes prepared from four different frogs and injected with water (n ϭ 45). PEPA (200 M) injected into oocytes (20 nl/oocyte) also did not elicit current responses (n ϭ 3). When the PEPA sample or frog Ringer's solution used in these experiments was analyzed by HPLC (the analysis system could detect concentrations exceeding 10 nM), no contaminating glutamate or aspartate peaks were detected. When it was applied by concentration jump to HEK 293 cells transfected with glutamate receptor subunits, PEPA (100 M) failed to activate rapidly desensitizing responses even in cells expressing AMPA receptors at high density. Because subsequent experiments revealed a profound potentiation of glutamate responses by PEPA, we focused our attention on the modulatory action of PEPA and have not yet determined In contrast, cyclothiazide caused the greatest potentiation in oocytes expressing GluRC i . The flop-selective action of PEPA resembles that of aniracetam, but clearly PEPA is considerably more potent; in fact, potentiation by 25 M PEPA for GluRC o responses (21.5 Ϯ 3.9-fold, n ϭ 7) was even larger than that produced by 25 M cyclothiazide for GluRC i responses (13.4 Ϯ 2.4-fold, n ϭ 6).
In an attempt to define accurately the differences in the potency for modulation of AMPA receptors by PEPA and aniracetam, we performed dose-response analyses in oocytes expressing GluRC o or GluRC i . Figure 3 shows potentiation by PEPA and aniracetam expressed as the fold increase in responses to 100 M glutamate when coapplied with modulator. Both aniracetam and PEPA were flop-preferring and produced much greater potentiation for GluRC o than for GluRC i at their limit of solubility in frog Ringer's solution. The EC 50 for potentiation of GluRC o by PEPA was 50 M (Hill coefficient ϭ 1.03). Aniracetam did not produce any detectable potentiation at 100 M, and at 1-2 mM it produced almost comparable potentiation to only 10 M PEPA. Although complete dose -response curves could not be constructed for aniracetam because of its limited solubility and low potency, our data indicate that PEPA was at least 100 times more potent for potentiation of GluRC o than aniracetam (Fig. 3) . Dose -response analysis of PEPA modulation for GluRC i suffered from similar limitations to those for analysis of the effects of aniracetam, and within the concentration range that it was possible to analyze we were unable to determine whether the maximum potentiation by PEPA for GluRC i was less than for GluRC o or whether, in addition, the EC 50 of PEPA for GluRC i was greater than the EC 50 for GluRC o .
The flop-preferring action of aniracetam has been reported previously for studies comparing GluR A o B o with GluRA i B i and GluRB o D o with GluRB i D i expressed in oocytes (Johansen et al., 1995) and for homomeric GluR A o compared with homomeric GluR A i expressed in H EK 293 cells (Partin et al., 1996) . To determine whether the selectivity of PEPA for GluRC o versus GluRC i was maintained in other AM PA receptor subunits, we compared potentiation of responses to glutamate by 200 M PEPA for GluR A, GluRC, and GluRD expressed alone and in combination with GluRB. Figure 4 shows that PEPA caused consistently greater enhancement of currents evoked by 100 M glutamate in oocytes expressing AM PA receptor flop versus flip isoforms for all subunits examined. However, there were clear differences among subunits and between homomeric receptors versus heteromeric receptors generated by coassembly with GluRB. GluRA o was the least sensitive of the flop variants, but nonetheless it showed greater potentiation than GluRA i (Fig. 4) . Coassembly with GluRB o increased potentiation by PEPA for GluRA o . In heteromeric receptors formed from GluRB and GluRC, the magnitude of enhancement by PEPA was dependent on the splice isoform of GluRC; although marked potentiation was observed for GluRB o C o , only moderate potentiation was observed for GluRB i C o , whereas GluRB i C i and GluRB o C i were potentiated only weakly. Because these subunits were injected at a ratio of 1:1, it is possible that the results obtained reflect formation of homomeric GluRC rather than a dominant effect of the GluRC subunit.
PEPA is selective for AMPA subclass ionotropic glutamate receptors
Next, we tested effects of PEPA on other glutamate receptor subtypes. Figure 5A shows traces obtained from two oocytes expressing GluR6, a kainate receptor subunit. The oocyte shown in the top traces was untreated, and that in the bottom traces was treated with concanavalin A to block desensitization, as described in Materials and Methods. For the untreated oocyte, responses to 100 M glutamate were separated by 10 min intervals to allow recovery from desensitization; then PEPA (100 M) and glutamate were applied simultaneously, and the oocyte was washed with Ringer's solution again for 10 min to confirm recovery. After treatment with concanavalin A, solutions were applied by using the same order but with applications of glutamate separated by 1 min intervals. In contrast to its effects on AMPA receptors, PEPA did not potentiate the glutamate-evoked currents for GluR6 (n ϭ 10) either before or after reduction of desensitization by concanavalin A; instead, PEPA caused a modest but reproducible inhibition, which was not observed with the 0.1% DMSO present in 100 M PEPA solutions. Similar experiments performed in oocytes expressing the kainate receptor subunits GluR6 plus KA2 (n ϭ 10) confirmed that there was also no potentiation by PEPA of these receptors (Fig. 5B) . Currents evoked by simultaneous application of glutamate and glycine (10 M each) in oocytes expressing the NMDA receptor subunits plus subunits Figure 3 . PEPA is much more potent than aniracetam. Shown are dose-response curves for potentiation of glutamate responses by PEPA and aniracetam (Ani) in oocytes expressing GluRC o and GluRC i . Glutamate (100 M) was applied first to oocytes to obtain control responses, and then solutions containing both glutamate and various concentrations of PEPA or aniracetam were applied. Ordinate, Fold potentiation is given as the amplitude of the response evoked by coapplication of glutamate plus modulator/amplitude of the response to glutamate alone. In the case of GluRC o , the dose-response curve for PEPA indicates the best fit to the data according to the logistic f unction ⑀1-⑀4 (n ϭ 11) also were not potentiated by PEPA (Fig. 5B) ; a very small response was elicited by glutamate without glycine in these oocytes, which also was not potentiated by PEPA (data not shown).
PEPA increases GluRC o apparent affinity for glutamate
Cyclothiazide has been shown previously to cause a leftward shift in the agonist dose -response relationship for native AMPA receptors in hippocampal neurons and for GluR A i expressed in oocytes (Patneau et al., 1993; Yamada and Tang, 1993; Partin et al., 1994) ; in contrast, it has been reported that aniracetam produces a shift to the right of the glutamate dose-response relationship for GluR A o (Tsuzuki et al., 1992) . In similar experiments we observed that PEPA (10 -100 M) causes a leftward shift in the glutamate dose -response relationship in oocytes expressing GluRC o (Fig. 6 A,B) . The apparent EC 50 and Hill coefficient values for glutamate were, respectively, 36 Ϯ 6 M and 1.2 (n ϭ 7) without PEPA, 10 Ϯ 1 M and 1.7 (n ϭ 7) in the presence of 10 M PEPA, and 5 Ϯ 1 M and 1.7 (n ϭ 4) in the presence of 100 M PEPA. Thus although flop-selective, the effects of PEPA on AMPA receptor affinity for glutamate resemble those of cyclothiazide as opposed to aniracetam.
Weak potentiation by PEPA of kainate-evoked currents at AMPA receptors Figure 7 compares the actions of PEPA (10 M) on glutamateevoked (100 M) and kainate-evoked (100 M) currents in oocytes expressing the flip or flop splice variants of GluRC. In oocytes expressing GluRC o , glutamate responses were much smaller than kainate responses (Fig. 7A,C) , such that the ratio of their amplitudes (I glu /I kai ) was 0.19 Ϯ 0.02 (n ϭ 10). This low value is attributable in part to stronger desensitization of responses to glutamate versus kainate at AM PA receptors Patneau et al., 1993) , a difference that is enhanced for flop versus flip splice variants (L omeli et al., 1994; Mosbacher et al., 1994; Partin et al., 1994) . Consistent with this, in oocytes expressing GluRC o the amplitude of glutamate responses (53 Ϯ 11 nA) was much smaller than for oocytes expressing GluRC i (258 Ϯ 27 nA), although the amplitude of equilibrium responses to kainate was similar for GluRC o (274 Ϯ 36 nA) and GluRC i (325 Ϯ 22 nA). As a result, the I glu /I kai ratio for GluRC i (0.77 Ϯ 0.04, n ϭ 7) was fourfold greater than for GluRC o .
The difference in I glu /I kai ratios for GluRC i versus GluRC o is of interest because PEPA potentiated glutamate responses for GluRC o to a much greater extent than kainate responses (Fig.  7A,D) , whereas for GluRC i , although potentiation by PEPA was weaker than for GluRC o , the extent of potentiation was similar for both agonists (Fig. 7B,D) . A similar agonist dependence for potentiation of AMPA receptor responses by aniracetam and cyclothiazide has been observed previously (Tsuzuki et al., 1992; Partin et al., 1994) . These results suggest that PEPA potentiates AMPA receptor responses at least in part by reducing desensitization.
PEPA suppresses AMPA receptor desensitization in HEK 293 cells
A widely recognized limitation of the use of two-electrode voltage-clamp recording from oocytes is that it is impossible to apply solutions rapidly enough to resolve the very rapid desensitization exhibited by AMPA receptors. Analysis of the effects of drugs on AMPA receptor responses is confounded further by subunit and splice variant-specific differences in the amount of desensitization of control responses to glutamate, such that the amplitudes of equilibrium currents expressed by AMPA receptors vary with subunit composition (Lomeli et al., 1994; Mosbacher et al., 1994; Partin et al., 1994) . One consequence of this would be that a receptor that normally desensitizes by 90% could be potentiated maximally only 10-fold by block of desensitization, whereas a receptor that normally desensitizes by 99% could be potentiated 100-fold. Thus, the apparent selectivity of PEPA for GluRC and GluRD might not reflect simply a higher affinity of PEPA for these subunits, because the inherently stronger desen- sitization for the flop splice variants of GluRC and GluRD (Lomeli et al., 1994; Mosbacher et al., 1994; Partin et al., 1994) also could increase potentiation of equilibrium responses to glutamate if the mechanism underlying potentiation by PEPA involved block of desensitization.
To address this issue, we used whole-cell recording with rapid perf usion to study recombinant AM PA receptor responses in transiently transfected H EK 293 cells. The kinetics of AMPA receptor desensitization was measured in response to concentration jump application of 3 mM glutamate in the absence or presence of 100 M PEPA (Fig. 8 A,B) . We also measured potentiation of equilibrium responses to glutamate in response to concentration jump application of PEPA (Fig. 8C) . The combined results of such analysis reveal that, for subunit combinations for which PEPA f ully blocks desensitization, differences in the extent of desensitization of control responses to glutamate indeed do appear to contribute to the extent of potentiation by PEPA. For example, although PEPA produced nearly complete block of desensitization for both GluRB o D o and GluRB i D i (Fig. 8 A,B) , potentiation of equilibrium responses to glutamate for these subunits suggested strong flop selectivity (GluRB o D o , 74 Ϯ 10.8-fold potentiation; GluRB i D i , 9.7 Ϯ 1.2-fold potentiation). Experiments with additional subunits provided f urther support for the hypothesis that the degree of potentiation by PEPA is determined in part by the extent of desensitization of control responses to glutamate; thus, as shown in Figure 8 D, the magnitude of potentiation by PEPA was related inversely to the amplitude of equilibrium responses to glutamate in the absence of PEPA. Subunit combinations for which the onset of desensitization has been shown to occur extremely rapidly-GluRC o , GluRD o , GluR-B o C o , and GluRB o D o -and that show the greatest extent of desensitization at equilibrium (Lomeli et al., 1994) showed much stronger potentiation by PEPA than did GluRA i , GluRD i , GluRA i B i , and GluRB i D i , subunit combinations for which the onset of desensitization is relatively slow and that show less desensitization of control responses to glutamate (Lomeli et al., 1994; Mosbacher et al., 1994) . The greater extent of potentiation by PEPA in HEK 293 cells (Fig. 8 D) than in oocytes (see Fig. 4 ) possibly reflects difficulties in accurately measuring the equilibrium amplitude of control responses to glutamate in HEK 293 cells transfected with strongly desensitizing subunits. In Xenopus oocytes we noticed that the extent of potentiation by PEPA for GluRC o and GluRD o was related inversely to the amplitude of control responses to glutamate, possibly also reflecting inaccuracy in measuring the amplitude of control responses for these strongly desensitizing subunits.
The results shown in Figure 8 suggest that PEPA directly affects the process of desensitization and that subunit-specific differences in the magnitude of PEPA potentiation are likely to reflect both the intrinsic desensitization properties of individual subunits as well as possible differences in affinity for PEPA. Although for some subunits (e.g., GluRC o and GluRD o ) the rate of desensitization of control responses to glutamate was too rapid to be measured accurately by whole-cell recording, for all subunit combinations tested both the rate of onset and amount of desensitization were strongly attenuated by PEPA, making it relatively easy to compare differences in desensitization kinetics among subunits in the presence of PEPA (Table 1) .
The results of such an analysis are shown in Figure 9 and emphasize both the selective modulation by PEPA of AMPA receptor flop splice variants as well as subunit-selective effects of PEPA. Thus, even for GluR A, the least sensitive subunit examined for which desensitization remained pronounced in the presence of PEPA for both flip and flop splice variants (Fig. 9A) , the time constant of onset of desensitization for GluRA o ( control , 8.0 Ϯ 0.4 msec; PEPA , 252 Ϯ 13 msec; n ϭ 14) was slowed by 100 M PEPA nearly three times more than for GluRA i ( control , 8.0 Ϯ 0.5 msec; PEPA , 89 Ϯ 6 msec; n ϭ 11). In addition, a residual fast-desensitizing component of time constant identical to that for control responses to glutamate and that accounted for 27 Ϯ 4% of the decay in the presence of 100 M PEPA suggests that for GluR A i the binding of PEPA is not saturated at 100 M, whereas for GluR A o desensitization in the presence of 100 M PEPA was well fit by a single exponential, suggesting that binding of PEPA to GluR A o is saturated at 100 M. Although the flopselective action of PEPA is indicated f urther by the complete block of desensitization by 100 M PEPA for GluRD o and GluR A o B o , but not GluRD i and GluR A i B i (Table 1 and (Table 1) , the subunit dependence for slowing of desensitization followed the rank order GluRD Ͼ GluRC Ͼ Ͼ GluR A (Fig. 9) .
The effects of PEPA were enhanced f urther by heteromerization with the corresponding flip or flop isoforms of GluRB, and the current observed after a 2 sec application of GLUϩPEPA approached 100% of peak in cells expressing GluRA o B o , GluR-B i C i , GluRB i D i , and GluRB o D o ; these subunit combinations, together with GluRD o , therefore were classified as effectively "nondesensitizing" within the limits of the current protocol (Fig.  9B) . In an attempt to differentiate among subunits that effectively were nondesensitizing during 2 sec applications of PEPAϩGLU, we also measured the kinetics of onset of ( on ) and recovery from ( off ) potentiation by PEPA in the continuous presence of glutamate (Fig. 8C, Table 1 ). Such experiments revealed responses to PEPA with kinetics more complex than that predicted by a simple model in which binding of PEPA blocks desensitization, because the response to removal of PEPA frequently showed both fast and slow components of decay of potentiation (Fig. 8C) . In addition, for flop subunits responses to glutamate in the presence of PEPA tended to show fast and slow components of activation and deactivation (Figs. 8 B, 9A) , indicating that the mechanism or mechanisms of action of PEPA are likely to be complex. Within these limitations and assuming that off approximates the inverse rate constant for dissociation of PEPA and that the rate constant for binding of PEPA does not differ among subunits, analysis that uses the protocol shown in Figure 8C gives an indirect measure of subunit-dependent differences in affinity for PEPA (Table 1 ). In cells expressing AMPA receptor flop isoforms, values for off in response to removal of PEPA were consistently slower than for the corresponding flip isoforms, suggesting a higher affinity of flop receptors for PEPA. However, between the fastest (GluRA i ; off , 87 Ϯ 7 msec) and slowest responding subunits (GluRD o ; off , 237 Ϯ 9 msec) there was only a threefold range in kinetics of recovery from potentiation, indicating that additional mechanisms must underlie subunit selective modulation by PEPA. Especially interesting is the comparison for responses to 100 M cyclothiazide recorded with similar protocols (Patneau et al., 1993; Partin et al., 1994) , which reveal that the onset of potentiation by 100 M PEPA develops ϳ50 -100 times faster than for cyclothiazide, although both drugs produce nearly complete block of desensitization for selected subunit combinations. The kinetics of recovery from potentiation by PEPA (Table 1 ) was also much Values are mean Ϯ SEM, in msec, for 3-20 cells per subunit. Examples illustrating analysis of des (Glu) and des (GluϩPEPA) are shown in Figures 8A and 9A ; analysis of equilibrium potentiation and the rate of onset ( ON ) and recovery ( OFF ) from potentiation by PEPA are shown in Figure 8B . *Indicates that 14 of 20 cells expressing GluRB O C O desensitized by 20.4% with a mean time constant of 564 msec, whereas six other cells desensitized by only 3.7%. **Estimated slowing of (GϩP)/(G) assumes a value of 2 sec for des (GluϩPEPA) in the case of subunit combinations for which desensitization in the presence of PEPA was either too slow or too small to perform the exponential analysis accurately. #Indicates that for only two of nine cells were control responses to glutamate large enough to estimate des accurately.
faster than that for recovery from potentiation by cyclothiazide (Patneau et al., 1993; Partin et al., 1994) .
DISCUSSION
Our results show that PEPA is a selective and potent modulator of AMPA subtype glutamate receptors, with preferential activity at flop splice variants. PEPA potentiates glutamate-evoked currents by slowing the rate of onset of desensitization and by increasing the apparent affinity of AMPA receptors for agonist. It is possible that PEPA also slows deactivation, but this was not tested in the present experiments. The effects of PEPA were much stronger for GluRC and GluRD versus GluRA, most likely reflecting either subunit-dependent differences in affinity and/or stronger desensitization of control responses to glutamate for GluRC and GluRD versus GluRA.
PEPA versus aniracetam
Comparison with previous work (Johansen et al., 1995; Partin et al., 1996) suggests that PEPA and aniracetam have similar subunit and splice-variant selectivity; however, PEPA is considerably more potent than aniracetam in potentiating AMPA receptor currents. In agreement with this, concentrations in excess of 1-5 mM aniracetam are required for strong potentiation of AMPA receptor currents in oocytes (Tsuzuki et al., 1992; Johansen et al., 1995) ; in fact, saturation of the dose-response relationship cannot be achieved because of the low affinity and limited solubility of aniracetam in physiological solutions. In contrast, PEPA effectively potentiates AMPA receptor responses at 10 -200 M concentrations. It was reported that 1 mM aniracetam potentiates glutamate-evoked currents ϳ2.5-fold in oocytes expressing GluRA o (Tsuzuki et al., 1992) , whereas a fivefold lower concentration of PEPA (200 M) potentiates GluRA o responses eightfold (Fig. 4) (Partin et al., 1996) , was much faster than in the presence of 100 M PEPA, 89 and 252 msec, respectively (Fig. 9) .
PEPA versus cyclothiazide
In the present study PEPA (25 M) was found to potentiate glutamate responses for GluRC o to a much greater extent than the same concentration of cyclothiazide, whereas the reverse was true for GluRC i (see Fig. 2C ). PEPA and cyclothiazide appear to have similar potency but opposite splice-variant selectivity; whereas PEPA preferentially modulates flop receptors, cyclothiazide has been shown to prefer flip isoforms (Partin et al., 1994 300 Ϯ 25 msec), indicating that the flop selectivity of PEPA for potentiation of GluRC equilibrium responses to glutamate most likely reflects differences in the extent of desensitization of control responses to glutamate. In contrast, for GluR A o the time constant of desensitization in the presence of 100 M PEPA (252 Ϯ 13 msec) was much slower than for GluR A i ( des , 89 Ϯ 6 msec), whereas for 100 M cyclothiazide desensitization was blocked almost f ully for GluR A i but remained pronounced for GluR A o (Partin et al., 1994 (Fig. 9) .
Mechanism of action of PEPA
A characteristic feature of allosteric modulation by PEPA, which is common also to aniracetam and cyclothiazide, is that each drug potentiates AM PA receptor currents by suppressing desensitization. However, it has been proposed recently that aniracetam and cyclothiazide suppress desensitization by different mechanisms (Partin et al., 1996) . K inetic modeling of the rapid deactivation and desensitization kinetics of GluR A i and GluR A o suggests that aniracetam slows the rate of channel closing, indirectly slowing the onset of desensitization, whereas cyclothiazide has a direct effect on the rate constant of desensitization and, in addition, stabilizes agonist-bound closed states, thus increasing agonist affinity and slowing deactivation. Whether this model is sufficient to explain the behavior of other subunits or of heteromeric subunit combinations remains to be determined. Although additional experiments are required to develop a kinetic model for the action of PEPA, our results show that PEPA does not behave exactly like aniracetam, because for some subunits PEPA completely prevented desensitization. If this were attributable exclusively to slowing of deactivation, as modeled for aniracetam modulation of GluR A (Partin et al., 1996) , we would expect a considerably more pronounced slowing of the current decay after removal of agonist than was observed in our experiments (Fig. 8) . Also, PEPA caused a leftward shift in the agonist dose-response relationship for GluRC o (Fig. 6 ) reminiscent of the action of cyclothiazide, but not aniracetam. A detailed analysis of deactivation kinetics in the presence of PEPA and experiments designed to resolve the origin of the slow onset of responses to glutamate in the presence of PEPA (Figs. 8, 9 ) will be necessary to understand how modulation by PEPA differs from that produced by aniracetam and cyclothiazide.
Drug design and receptor structure-function analysis
When the chemical structures are compared among aniracetam, cyclothiazide, and PEPA (see Fig. 1 ), no obvious features common to all three drugs are seen. There is, however, a sulfonylamino group (-SO 2 N H-) common to PEPA, cyclothiazide, and other benzothiadiazines that has been shown to suppress AMPA receptor desensitization (Bertolino et al., 1993; Yamada and Tang, 1993) . The fact that this f unctional group is not found in aniracetam suggests that it might be important for coupling drug binding to modulation of desensitization versus channel-gating kinetics.
Although the actions of aniracetam and cyclothiazide are different, it has been shown previously that modulation by both drugs is sensitive to a single amino acid residue in the flip/flop domain (Partin et al., 1995) . This position contains a serine residue in flip splice variants, an asparagine residue in flop splice variants, and a glutamine residue at the equivalent site in cyclothiazide-insensitive kainate receptors (S/N/Q site). Exchange of the serine and asparagine residues by site-directed mutagenesis (GluRA i S750N and GluRA o N750S) is sufficient to exchange flip-like and flop-like modulation by aniracetam and cyclothiazide (Partin et al., 1995 (Partin et al., , 1996 . Preliminary observations in HEK 293 cells expressing GluRA i S750N and in oocytes expressing the corresponding GluRC i mutant S758N confirm that this site also is involved in the action of PEPA and that the exchange of serine for asparagine is sufficient to convert flip-like to flop-like modulation (data not shown). Furthermore, in HEK 293 cells sensitivity to cyclothiazide, but not PEPA or aniracetam, is abolished for the mutant GluRA i S750Q. It remains to be determined, however, whether the S/N/Q site contributes to a binding site for these drugs or is involved in directing a conformational transition on which all three drugs converge.
Recently, a three-dimensional model for non-NMDA glutamate receptors has been proposed (Sutcliffe et al., 1996) . This model proposes a disulfide bond linking two highly conserved Cys residues, which are located in a large extracellular loop between the M3 and M4 domains (Hollmann et al., 1994; Stern-Bach et al., 1994; Bennett and Dingledine, 1995) . One of these Cys residues is located in the S2 domain, one of two putative agonist-binding domains that show structural homology with bacterial periplasmic lysine/arginine/ornithine binding protein (LAOBP; Stern-Bach et al., 1994) . The other is located in the flip/flop segment, which is implicated in deactivation and desensitization Partin et al., 1996) . Formation of a disulfide bond between these residues may be important for the actions of cyclothiazide and PEPA, because these drugs affect apparent affinity for both agonist and channel kinetics.
Pharmacological and physiological significance of allosteric modulation
Because of its strong preference for flip isoforms, cyclothiazide has been used to infer the splice-variant composition of native AMPA receptors in subpopulations of hippocampal neurons . Cyclothiazide also has been useful in examining the relationship between desensitization and synaptic efficacy. Similarities in the rate of AMPA receptor desensitization and the rate of synaptic current decay in certain neuronal populations suggest that at some synapses the rapid onset of AMPA receptor desensitization may serve to limit the duration of the excitatory postsynaptic response and/or induce postsynaptic depression (Trussell and Fischbach, 1989; Otis et al., 1996) . However, although both cyclothiazide (Trussell et al., 1993; Yamada and Tang, 1993; Raman et al., 1994) and aniracetam (Isaacson and Nicoll, 1991; Tang et al., 1991; Vyklicky et al., 1991; Hestrin, 1992) have been shown to enhance the peak amplitude and prolong the duration of excitatory postsynaptic currents, at many synapses this most likely results from a combination of presynaptic effects and a reduced rate of channel closing rather than from block of desensitization (Hestrin, 1992; Diamond and Jahr, 1995) . For this reason further work to establish the mechanism or mechanisms by which PEPA modulates AM PA receptors will be required before it would be wise to use this drug to investigate the role of AM PA receptor subtypes in synaptic transmission. In addition, it should be noted that, because PEPA was synthesized in the process of developing thromboxane A2 antagonists, it is possible that it could act on targets distinct from glutamate receptors; we established that PEPA is selective for AMPA versus kainate and NMDA receptors, but its effects on other receptor species have not yet been investigated.
Other studies have suggested that the memory-and cognitionenhancing properties of the pyrrolidinone-and benzothiadiazinecontaining drugs are related to their ability to enhance synaptic transmission via modulation of AM PA receptor gating (Arai et al., 1994; Staubli et al., 1994a,b; Johansen et al., 1995; Zivkovic et al., 1995) . In this regard, PEPA may be usef ul as a pharmacological tool and could provide new clues in the search for novel and more potent drugs affecting memory and cognition.
